AbCellera to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023Business Wire • 01/04/23
AbCellera and Rallybio Announce Strategic Alliance to Discover, Develop, and Commercialize Novel Antibody-Based Therapeutics for Rare DiseasesBusiness Wire • 12/01/22
AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022Business Wire • 11/10/22
AbCellera's First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical DevelopmentBusiness Wire • 11/02/22
AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 11/01/22
Wall Street Analysts Believe AbCellera Biologics Inc. (ABCL) Could Rally 138%: Here's is How to TradeZacks Investment Research • 10/21/22
AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022Business Wire • 10/05/22
AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the ClinicBusiness Wire • 09/21/22
AbCellera Biologics Inc. (ABCL) CEO Dr. Carl Hansen on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for PatientsBusiness Wire • 08/03/22
AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: Should You Buy?Zacks Investment Research • 08/02/22
Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech CompaniesBusiness Wire • 07/27/22